Protein Kinase Inhibitors: all 15,766 studies that test it

Page 147 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetic Investigation of UDCA in Bile and SerumCompletedNCT00529009Phase 1
• A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid TumorsCompletedNCT00528619Phase 1
• A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding PhaseCompletedNCT00528281Phase 1
• Study of XL228 Administered Intravenously to Subjects With Advanced MalignanciesTerminatedNCT00526838Phase 1
• BI 2536 in Treating Patients With Recurrent or Metastatic Solid TumorsCompletedNCT00526149Phase 2
• Proleukin and Rapamune in Type 1 DiabetesCompletedNCT00525889Phase 1
• A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic MalignanciesCompletedNCT00523432Phase 1
• Study to Assess the Safety of Escalating Doses of AT9283, in Patients With LeukemiasTerminatedNCT00522990Phase 1/2
• Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT00522938Phase 1/2
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal CancerCompletedNCT00522665Phase 1/2
• A Safety Study of XL019 in Adults With MyelofibrosisTerminatedNCT00522574Phase 1
• Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCCTerminatedNCT00522249Phase 1/2
• Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or ErlotinibCompletedNCT00522145Phase 2
• Sunitinib Malate in Treating East African Patients With Kaposi SarcomaWithdrawnNCT00521092Phase 2
• Safety and Tolerability Study of SNS-314 for Advanced Solid TumorsCompletedNCT00519662Phase 1
• Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric CancerCompletedNCT00519324Phase 2
• Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant PatientsCompletedNCT00519116Phase 4
• MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)CompletedNCT00518739Phase 1
• Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With SirolimusCompletedNCT00518375Phase 4
• Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft RecipientsCompletedNCT00518271Phase 2
• Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00517920Phase 2
• Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT00517790Phase 2
• A Study to Examine the Effect of Particle Size on Bioequivalence and BioavailabilityCompletedNCT00517543Phase 1
• Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid TumorsCompletedNCT00516672Phase 1
• Enzastaurin and Temozolomide in Treating Patients With Primary GliomasStatus unknownNCT00516607Phase 1
• Phase I Study of BMS-690514 in Japanese Patients With Solid TumorsCompletedNCT00516451Phase 1
• Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00516412Phase 2
• Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic PhaseCompletedNCT00514969Phase 2
• Ursodiol in Huntington's DiseaseStatus unknownNCT00514774Phase 1
• Phase II Efficacy Study of AZD6244 in Colorectal CancerCompletedNCT00514761Phase 2
• Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)CompletedNCT00514488Phase 3
• Study of Intermittent OSI-906 DosingCompletedNCT00514306Phase 1
• Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT00514228Phase 2
• Study of Continuous OSI-906 DosingCompletedNCT00514007Phase 1
• Phase 1 Study of OSI-930 in Cancer PatientsCompletedNCT00513851Phase 1
• A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of LapatinibWithdrawnNCT00513253Phase 1
• Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerCompletedNCT00513058Phase 1
• Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate CancerTerminatedNCT00512668Phase 1
• Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid TumorsCompletedNCT00511849Phase 1
• Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid LeukemiaCompletedNCT00511303Phase 2
• Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)TerminatedNCT00511121Phase 2
• PTK787 in Refractory or Relapsed Diffuse Large Cell LymphomaTerminatedNCT00511043Phase 2
• Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT00510926Phase 2
• Thyroid Cancer and SunitinibCompletedNCT00510640Phase 2
• Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateCompletedNCT00510354Phase 4
• A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical CancerCompletedNCT00510250Phase 1/2
• Phase 1 Study With Sorafenib and SirolimusCompletedNCT00509613Phase 1
• Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00509431Phase 1
• A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid ArthritisCompletedNCT00508768Phase 1
• PTC299 and Hormonal Agent for Treatment of Metastatic Breast CancerCompletedNCT00508586Phase 1
• Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving SirolimusCompletedNCT00507793Phase 4
• Phase I Irinotecan, 5-Fluorouracil and Leucovorin CombinationCompletedNCT00507091Phase 1
• ZD6474(Vandetanib) + Alimta Combo StudyCompletedNCT00506051Phase 1
• Safe Renal Function In Long Term Heart Transplanted PatientsStatus unknownNCT00505102Phase 4
• Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant RecipientsCompletedNCT00504543Phase 2
• Enzastaurin in Treating Young Patients With Refractory Primary CNS TumorsCompletedNCT00503724Phase 1
• Phase I Chinese PKCompletedNCT00503711Phase 1
• A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in JapanCompletedNCT00503477Phase 1
• Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic TumorsCompletedNCT00503412Phase 1
• Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourCompletedNCT00503204Phase 1
• A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid TumorsCompletedNCT00502567Phase 1
• Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AMLCompletedNCT00502385Phase 1
• Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate CancerCompletedNCT00502164Phase 1
• Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced CancerCompletedNCT00502060Phase 1
• Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver MetastasesCompletedNCT00501605Phase 1
• FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal CancerCompletedNCT00501410Phase 1
• Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GISTCompletedNCT00500188Phase 2
• A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)TerminatedNCT00500006Phase 1
• Phase I FOLFOX CombinationCompletedNCT00499850Phase 1
• Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult SubjectsCompletedNCT00499538Phase 1
• Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast CancerStatus unknownNCT00499525Phase 2
• Ph II Study of Perifosine for Patients With Carcinoma of the KidneyCompletedNCT00498966Phase 2
• Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant MelanomaCompletedNCT00498836Phase 2
• Study Comparing 2 New Formulations of HKI-272 in Healthy Adult SubjectsCompletedNCT00498745Phase 1
• Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00497991Phase 1
• AZD1152 in Patients With Advanced Solid Malignancies-Study 1TerminatedNCT00497731Phase 1
• AZD1152 in Patients With Advanced Solid Malignancies-Study 3TerminatedNCT00497679Phase 1
• Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based ChemotherapyStatus unknownNCT00497250Phase 1
• Phase II Trial of Erlotinib in Advanced Pancreatic CancerCompletedNCT00497224Phase 2
• ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast CancerCompletedNCT00496665Phase 1
• Phase I Study of Patupilone and RAD001CompletedNCT00496600Phase 1
• Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal CancerCompletedNCT00496509Phase 1
• MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)CompletedNCT00496353Phase 1/2
• Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCCCompletedNCT00496301Phase 2
• Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLCCompletedNCT00496275Phase 1
• A Phase I/II Study of Sunitinib and DacarbazineTerminatedNCT00496223Phase 1/2
• Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerActive, not recruitingNCT00494182Phase 2
• Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693TerminatedNCT00493818Phase 1
• Fibrosis in Renal AllograftsStatus unknownNCT00493194Phase 4
• A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.CompletedNCT00493155Phase 1
• An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT00492986Phase 3
• Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney TransplantationCompletedNCT00492869Phase 1/2
• Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant GliomasStatus unknownNCT00492687Phase 2
• Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III MelanomaStatus unknownNCT00492505Phase 2
• Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerCompletedNCT00492258Phase 3
• Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast CancerStatus unknownNCT00491816Phase 2
• Safety Study of XL999 in Adults With Non-Small-Cell Lung CancerTerminatedNCT00491699Phase 1
• Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetyCompletedNCT00491517Phase 2
• Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMStatus unknownNCT00490789Phase 2
• Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00490685Phase 2

← Protein Kinase Inhibitors overview